Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Further Reading from MarketBeat Media Why 2 Small Biotechs May Hold the Key to New Cancer TreatmentsWritten by Nathan Reiff. Article Published: 3/12/2026. 
Quick Look - Iovance and ImmunityBio each have a leading oncology product that has helped to massively boost sales and share prices in recent quarters.
- Despite major gains in recent trading, IOVA and IBRX shares still have at least 70% in upside potential going forward, according to analysts.
- Profitability remains a concern for both companies, even as sales of their top cancer drugs have surged.
Cancer remains one of the greatest medical challenges for biotechnology firms, even as the oncology market is expected to grow to $366 billion over the next eight years. Many companies take a niche approach, developing medicines that target specific cancer types with dedicated mechanisms. Several promising treatments have shown strong potential—and with that comes the possibility of significant revenue. Two smaller biotech companies are experiencing notable share-price momentum thanks to their oncology medicines. Beyond clinical promise, these drugs could help the firms move past penny-stock or otherwise volatile status toward long-term profitability. But challenges remain, so these remain high-risk investments that could, for willing investors, generate outsized rewards. Iovance's Powerful Cancer Drug Is Growing, But Production Challenges Are a Hurdle A major force in the crypto world is quietly becoming one of gold's most aggressive buyers — and most investors have no idea it's happening.
A longtime gold analyst says profits from a leading stablecoin operation are being funneled into physical gold at a scale that could materially impact supply and demand. After a recent meeting with insiders, he began outlining what this trend could mean for gold prices and a small group of companies positioned to benefit. Read the full gold briefing here Iovance Biotherapeutics Inc. (NASDAQ: IOVA) defied market trends in early March, surging nearly 37% in a week when the S&P 500 dipped about 1%. That added to IOVA's year-to-date performance, which has more than doubled. Still, with a consensus price target of $8.88, Wall Street anticipates further gains—that target implies roughly 71% upside from current levels. The primary catalyst for Iovance's rally is its lead drug, Amtagvi, a T-cell immunotherapy for certain types of melanoma. Amtagvi has been approved for melanoma in the United States since 2024 and is building momentum in sales and regulatory progress, with additional approvals likely in the E.U., U.K., and elsewhere. When administered with Proleukin, the company's IL-2 immunotherapy, management believes Amtagvi has the potential to exceed $1 billion in U.S. peak sales. Amtagvi's broader potential may extend beyond melanoma: the drug received FDA Fast Track Designation for non-small cell lung cancer and could be effective against multiple other tumors. Some of Iovance's outperformance this year also followed its Q4 2025 earnings report, issued in late February, in which the company reported a narrower-than-expected loss per share and $5 million in revenue. For the full year, revenue rose by about 30% year-over-year (YOY). Iovance remains a relatively small-cap name (around $2 billion) and is still treated like a penny stock by many investors. Despite the rally, analysts remain cautious: roughly half of its dozen or so analyst ratings are either Hold or Sell. A key risk is Amtagvi's personalized, costly, and complex manufacturing process, which could constrain profitability even as demand grows. Massive Sales Growth for ImmunityBio's Bladder Cancer Drug ImmunityBio Inc. (NASDAQ: IBRX) fell about 20% in March, but its year-to-date performance dwarfs Iovance's. IBRX shares are up nearly 300% in 2026 alone, and this rally may be just the beginning. Analysts have set a price target of $13.60, roughly 70% above the stock's current price even after the recent gains. ImmunityBio's leading product and primary growth driver is Anktiva, a therapy for specific types of bladder cancer. In February, shares jumped after the E.U. regulator granted the drug conditional marketing authorization, the latest in a series of approvals worldwide. Anktiva is already driving revenue: the drug generated $113 million in sales last year, roughly a 700% YOY increase. Like Amtagvi, Anktiva may have potential in other cancer types, and ImmunityBio is actively exploring additional indications. Despite the recent surge, IBRX remains a speculative and risky investment. IBRX reported a full-year net loss of $351 million for 2025 as R&D spending continued to rise. Analysts appear somewhat more bullish on ImmunityBio than on Iovance: six of seven covering analysts rate the stock a Buy or equivalent.
| 
